MOVE.SW Medacta (SIX) intraday -6.58% to CHF156.20 04 Feb: watch CHF154.80

The MOVE.SW stock slid 6.58% intraday to CHF156.20 on 04 Feb 2026 as profit taking hit after recent gains. Volume rose to 11,438 shares versus an average of 13,245. The intraday low was CHF154.80, which traders view as immediate support. This drop places Medacta Group S.A. (MOVE.SW) among the top losers on the SIX Switzerland session and sharpens focus on valuation and near-term catalysts.

Intraday snapshot: MOVE.SW stock performance

MOVE.SW opened at CHF160.00 and traded between CHF154.80 and CHF160.00 today. The stock moved from a previous close of CHF167.20, a fall of CHF11.00 (-6.58%). Market cap stands near CHF3.15B and shares outstanding are 19,944,514. The 50-day average is CHF159.45 and the 200-day average is CHF146.98, which frames today’s price action against recent trend levels.

Why MOVE.SW fell: drivers behind the top loser move

Short-term selling followed an overbought technical picture. RSI sits at 74.52, and MFI is 85.90, both signaling heavy short-term buying exhaustion. Elevated PE and profit-taking also weighed on the name. MOVE.SW trades at a PE of 36.24 against a healthcare sector average of 34.55, which may prompt rotation by valuation-sensitive funds.

Fundamentals and valuation for MOVE.SW stock

Medacta reported trailing EPS of 4.36, and revenue per share stands at 32.39. Key ratios include PB 8.10 and EV/EBITDA 20.33. Free cash flow yield is low at 0.79%, while return on equity is 23.61%. These metrics show strong profitability but rich near-term valuation relative to peers in Medical – Devices.

Technical levels and Meyka AI grade & technical view

Immediate support is CHF154.80 with resistance near the 50-day average at CHF159.45. Bollinger middle is CHF156.03 and ATR is 3.29, implying intraday swings of roughly CHF3. An overbought CCI at 123.57 suggests short-term pullback risk.

Meyka AI rates MOVE.SW with a score out of 100: 74.46 / B+ — BUY. This grade factors in S&P 500 and sector comparisons, financial growth, forecast models, key metrics, and analyst signals. These grades are model outputs and are not guaranteed. We are not financial advisors.

Forecasts, targets and catalysts for MOVE.SW stock

Meyka AI’s forecast model projects monthly CHF177.78 and yearly CHF223.19. Versus the current CHF156.20, the monthly projection implies about 13.82% upside and the yearly projection implies about 42.90% upside. Key catalysts include the next earnings release on 13 Mar 2026 and ongoing product adoption in orthopedics. Forecasts are model-based projections and not guarantees.

Risks, trading strategy and sector context

Primary risks include valuation re-rating, slower elective surgery volumes, and inventory cycles; inventory days stand at 466.37. The healthcare sector has YTD strength, but MOVE.SW’s short-term volatility is higher. Traders may use layered entries with stops under CHF154.80 or wait for a reclaim above CHF159.45. This is a risk-managed approach, not investment advice.

Final Thoughts

MOVE.SW stock fell intraday to CHF156.20, marking a 6.58% pullback into short-term support at CHF154.80. The sell-off reflects overbought technical signals and relative valuation pressure versus healthcare peers. Fundamentals show solid profitability, with EPS 4.36 and ROE 23.61%, but price multiples remain rich (PE 36.24, PB 8.10). Meyka AI’s model projects CHF177.78 for the next month, an implied 13.82% upside from today’s price, and CHF223.19 over 12 months. Investors should weigh the upside against inventory intensity and short-term volatility. For active traders, a tight stop below CHF154.80 may limit losses. For longer-term investors, watch earnings on 13 Mar 2026 for fresh guidance. Meyka AI provides this as AI-powered market analysis; forecasts are model-based and not guaranteed.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.